BIOMAT Database Logo BIOMAT Database Logo

Monoclonal antibodies against ovarian carcinoma-associated antigens, raised by immunization with cyst fluids. 1989

O Boerman, and K Makkink, and L Massuger, and C Thomas, and P Kenemans, and T Hanselaar, and L Poels
Department of Cell Biology, Medical Faculty University of Nijmegen, The Netherlands.

Intrasplenic immunization with ovarian tumour derived cyst fluids was used to generate monoclonal antibodies (Mabs) against human ovarian carcinomas. Seven Mabs were characterized immunocytochemically using indirect immunofluorescence assays (IFA) on frozen sections of gynaecologic tumours (n = 85), non-gynaecologic tumours (n = 50), normal human tissues (n = 66), and on 8 ovarian carcinoma cell lines. The Mabs reacted with 67-96% of 49 ovarian carcinoma tissues tested. Although 6 out of 7 Mabs showed slight cross reactivity with some endometrial, cervical, and oviductal carcinomas, little reactivity with non-gynaecologic tumours or normal tissues was found. Based on immunoelectronmicroscopy, all the antigenic determinants defined by the Mabs appeared to be associated with the tumour cell membrane. Among the seven Mabs, OV-TL 16 (IgG1 subclass) and OV-TL 23 (IgM class) reacted positively with 96% and 82% of the ovarian carcinomas respectively. Staining of 100% of the ovarian carcinomas examined (n = 49) could be achieved by combining OV-TL 16 with 23, as also by other combinations of the Mabs. It is concluded that a panel of these newly developed Mabs may be suitable for diagnostic purposes in histopathology.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D010048 Ovarian Cysts General term for CYSTS and cystic diseases of the OVARY. Corpus Luteum Cyst,Corpus Luteum Cysts,Cyst, Corpus Luteum,Cyst, Ovarian,Cysts, Corpus Luteum,Cysts, Ovarian,Ovarian Cyst
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006825 Hybridomas Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell. Hybridoma
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor

Related Publications

O Boerman, and K Makkink, and L Massuger, and C Thomas, and P Kenemans, and T Hanselaar, and L Poels
Monoclonal antibodies raised to colorectal carcinoma antigens.
November 1986, Annals of the Royal College of Surgeons of England,
O Boerman, and K Makkink, and L Massuger, and C Thomas, and P Kenemans, and T Hanselaar, and L Poels
Clinical applications of monoclonal antibodies against ovarian cancer-associated antigens.
November 1988, European journal of obstetrics, gynecology, and reproductive biology,
O Boerman, and K Makkink, and L Massuger, and C Thomas, and P Kenemans, and T Hanselaar, and L Poels
Monoclonal mouse antibodies raised against human lung carcinoma.
August 1986, Cancer research,
O Boerman, and K Makkink, and L Massuger, and C Thomas, and P Kenemans, and T Hanselaar, and L Poels
Immunization effect of monoclonal antibodies against tumor-associated antigens during cancer treatment.
August 1993, Annals of the New York Academy of Sciences,
O Boerman, and K Makkink, and L Massuger, and C Thomas, and P Kenemans, and T Hanselaar, and L Poels
[Monoclonal antibodies against tumor associated antigens].
March 1988, Human cell,
O Boerman, and K Makkink, and L Massuger, and C Thomas, and P Kenemans, and T Hanselaar, and L Poels
Monoclonal antibodies raised against NeuAc alpha 2-6neolactotetraosylceramide detect carcinoma-associated gangliosides.
July 1985, Biochimica et biophysica acta,
O Boerman, and K Makkink, and L Massuger, and C Thomas, and P Kenemans, and T Hanselaar, and L Poels
Oncofetal antigens in ovarian cyst fluids.
January 1984, Gynecologic and obstetric investigation,
O Boerman, and K Makkink, and L Massuger, and C Thomas, and P Kenemans, and T Hanselaar, and L Poels
Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity.
March 1987, International journal of cancer,
O Boerman, and K Makkink, and L Massuger, and C Thomas, and P Kenemans, and T Hanselaar, and L Poels
Production of murine monoclonal antibodies against cell-surface antigens of human ovarian carcinoma.
December 1985, Journal of surgical oncology,
O Boerman, and K Makkink, and L Massuger, and C Thomas, and P Kenemans, and T Hanselaar, and L Poels
Characterization of mucin antigens recognized by monoclonal antibodies raised against human colon cancer cells.
January 1991, Cancer research,
Copied contents to your clipboard!